ACTUATE THERAPEUTICS, INC.
Actuate Therapeutics, Inc. (Nasdaq: ACTU) is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β). The company's website is www.actuatetherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ACTUATE THERAPEUTICS, INC. does
In the company’s own words
Actuate Therapeutics, Inc. (Nasdaq: ACTU) is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β). The company's website is www.actuatetherapeutics.com.
The company's lead product candidate is elraglusib, an ATP-competitive small molecule inhibitor designed to block GSK-3β signaling, a master regulator of biological cascades that drive tumor cell survival, growth, migration, and invasion. Elraglusib represents what the company describes as a "pipeline in a molecule" due to its multimodal mechanisms of action and potential application across multiple cancer indications. The company has exclusively licensed elraglusib from a collaboration between the University of Illinois-Chicago and Northwestern University.
Actuate has developed elraglusib in two formulations: Elraglusib Injection for intravenous administration and Elraglusib Oral Tablet for oral delivery. The company has treated over 500 patients with elraglusib across Phase 1 and Phase 2 studies. The most advanced program involves a Phase 2 trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), which met its primary endpoint of median overall survival improvement, demonstrating a statistically significant benefit when elraglusib was combined with gemcitabine/nab-paclitaxel versus chemotherapy alone.
Beyond mPDAC, the company is evaluating elraglusib in pediatric cancers including Ewing sarcoma and neuroblastoma, where initial clinical data showed promising responses. The company has received regulatory designations including Orphan Drug Designation for pancreatic cancer and other cancer types, Fast Track Designation for pancreatic cancer, and Rare Pediatric Disease Designation for Ewing sarcoma. The company is also exploring investigator-initiated trials evaluating elraglusib in combination with other chemotherapy regimens and immunotherapies.
Actuate operates as a clinical-stage company with no approved products currently on the market. The company's strategy focuses on advancing elraglusib through clinical development while pursuing strategic partnerships and regulatory incentives to accelerate the path to potential approval across multiple cancer indications.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- FORT WORTH, TX
- Fiscal year end
- December
- CIK
- 1652935
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ACTUATE THERAPEUTICS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ACTUATE THERAPEUTICS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ACTUATE THERAPEUTICS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ACTUATE THERAPEUTICS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ACTUATE THERAPEUTICS, INC.'s last four quarterly filings that the numbers alone won't show?”